Mutational Landscape and Precision Medicine in Hepatocellular Carcinoma

被引:4
作者
Gorji, Leva [1 ]
Brown, Zachary J. [2 ]
Pawlik, Timothy M. [3 ,4 ]
机构
[1] Kettering Hlth Dayton, Dept Surg, Dayton, OH 45405 USA
[2] New York Univ Long Isl, Dept Surg, Div Surg Oncol, Mineola, NY 11501 USA
[3] Ohio State Univ, Wexner Med Ctr, Dept Surg, Div Surg Oncol, Columbus, OH 43210 USA
[4] James Canc Hosp, Columbus, OH 43210 USA
关键词
precision medicine; hepatocellular carcinoma; targeted therapy; ATEZOLIZUMAB PLUS BEVACIZUMAB; DOUBLE-BLIND; INTEGRATED ANALYSIS; OPEN-LABEL; CANCER; LIVER; SORAFENIB; EXPRESSION; ARID1A; GENES;
D O I
10.3390/cancers15174221
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Hepatocellular carcinoma (HCC) continues to manifest a global burden with increasing incidence. Although many treatment modalities exist, the disease process is plagued with high recurrence and mortality. The comprehension of the mutation landscape of the disease in conjunction with the use of precision medicine will aid in individualized, targeted therapies for treatment. Through understanding the tumor microenvironment, management of the malignancy may be optimized. The purpose of our review is to emphasize the role and prospects of precision medicine in the treatment of HCC.Abstract Hepatocellular carcinoma (HCC) is the fourth most common malignancy worldwide and exhibits a universal burden as the incidence of the disease continues to rise. In addition to curative-intent therapies such as liver resection and transplantation, locoregional and systemic therapy options also exist. However, existing treatments carry a dismal prognosis, often plagued with high recurrence and mortality. For this reason, understanding the tumor microenvironment and mutational pathophysiology has become the center of investigation for disease control. The use of precision medicine and genetic analysis can supplement current treatment modalities to promote individualized management of HCC. In the search for personalized medicine, tools such as next-generation sequencing have been used to identify unique tumor mutations and improve targeted therapies. Furthermore, investigations are underway for specific HCC biomarkers to augment the diagnosis of malignancy, the prediction of whether the tumor environment is amenable to available therapies, the surveillance of treatment response, the monitoring for disease recurrence, and even the identification of novel therapeutic opportunities. Understanding the mutational landscape and biomarkers of the disease is imperative for tailored management of the malignancy. In this review, we summarize the molecular targets of HCC and discuss the current role of precision medicine in the treatment of HCC.
引用
收藏
页数:20
相关论文
共 138 条
[1]   ARID1A expression in hepatocellular carcinoma and relation to tumor recurrence after microwave ablation [J].
Abdel-Moety, Aly ;
Baddour, Nahed ;
Salem, Perihan ;
Rady, Amr ;
El-Shendidi, Assem .
CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2022, 8 (01) :49-59
[2]   Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].
Abou-Alfa, G. K. ;
Meyer, T. ;
Cheng, A. -L. ;
El-Khoueiry, A. B. ;
Rimassa, L. ;
Ryoo, B. -Y. ;
Cicin, I. ;
Merle, P. ;
Chen, Y. H. ;
Park, J. -W. ;
Blanc, J. -F. ;
Bolondi, L. ;
Klumpen, H. -J. ;
Chan, S. L. ;
Zagonel, V. ;
Pressiani, T. ;
Ryu, M. -H. ;
Venook, A. P. ;
Hessel, C. ;
Borgman-Hagey, A. E. ;
Schwab, G. ;
Kelley, R. K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63
[3]   Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA [J].
Abou-Alfa, Ghassan K. ;
Chan, Stephen Lam ;
Kudo, Masatoshi ;
Lau, George ;
Kelley, Robin Kate ;
Furuse, Junji ;
Sukeepaisarnjaroen, Wattana ;
Kang, Yoon-Koo ;
Dao, Tu V. ;
De Toni, Enrico N. ;
Rimassa, Lorenza ;
Breder, Valeriy Vladimirovich ;
Vasilyev, Alexander ;
Heurgue, Alexandra ;
Tam, Vincent ;
Mody, Kabir ;
Thungappa, Satheesh Chiradoni ;
He, Philip ;
Negro, Alejandra ;
Sangro, Bruno .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[4]   Mass spectrometry-based proteomics [J].
Aebersold, R ;
Mann, M .
NATURE, 2003, 422 (6928) :198-207
[5]   Genomic Portrait of Resectable Hepatocellular Carcinomas: Implications of RB1 and FGF19 Aberrations for Patient Stratification [J].
Ahn, Sung-Min ;
Jang, Se Jin ;
Shim, Ju Hyun ;
Kim, Deokhoon ;
Hong, Seung-Mo ;
Sung, Chang Ohk ;
Baek, Daehyun ;
Haq, Farhan ;
Ansari, Adnan Ahmad ;
Lee, Sun Young ;
Chun, Sung-Min ;
Choi, Seongmin ;
Choi, Hyun-Jeung ;
Kim, Jongkyu ;
Kim, Sukjun ;
Hwang, Shin ;
Lee, Young-Joo ;
Lee, Jong-eun ;
Jung, Wang-rim ;
Jang, Hye Yoon ;
Yang, Eunho ;
Sung, Wing-Kin ;
Lee, Nikki P. ;
Mao, Mao ;
Lee, Charles ;
Zucman-Rossi, Jessica ;
Yu, Eunsil ;
Lee, Han Chu ;
Kong, Gu .
HEPATOLOGY, 2014, 60 (06) :1972-1982
[6]   Precision medicine: A new paradigm in therapeutics [J].
Akhoon, Neha .
INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 2021, 12 (01)
[7]   The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015 [J].
Akinyemiju, Tomi ;
Abera, Semaw ;
Ahmed, Muktar ;
Alam, Noore ;
Alemayohu, Mulubirhan Assefa ;
Allen, Christine ;
Al-Raddadi, Rajaa ;
Alvis-Guzman, Nelson ;
Amoako, Yaw ;
Artaman, Al ;
Ayele, Tadesse Awoke ;
Barac, Aleksandra ;
Bensenor, Isabela ;
Berhane, Adugnaw ;
Bhutta, Zulfiqar ;
Castillo-Rivas, Jacqueline ;
Chitheer, Abdulaal ;
Choi, Jee-Young ;
Cowie, Benjamin ;
Dandona, Lalit ;
Dandona, Rakhi ;
Dey, Subhojit ;
Dicker, Daniel ;
Phuc, Huyen ;
Ekwueme, Donatus U. ;
Zaki, Maysaa El Sayed ;
Fischer, Florian ;
Furst, Thomas ;
Hancock, Jamie ;
Hay, Simon I. ;
Hotez, Peter ;
Jee, Sun Ha ;
Kasaeian, Amir ;
Khader, Yousef ;
Khang, Young-Ho ;
Kumar, G. Anil ;
Kutz, Michael ;
Larson, Heidi ;
Lopez, Alan ;
Lunevicius, Raimundas ;
Malekzadeh, Reza ;
McAlinden, Colm ;
Meier, Toni ;
Mendoza, Walter ;
Mokdad, Ali ;
Moradi-Lakeh, Maziar ;
Nagel, Gabriele ;
Nguyen, Quyen ;
Nguyen, Grant ;
Ogbo, Felix .
JAMA ONCOLOGY, 2017, 3 (12) :1683-1691
[8]   The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention [J].
Alao, John P. .
MOLECULAR CANCER, 2007, 6 (1)
[9]  
Allaire M, 2020, JHEP REP, V2, DOI 10.1016/j.jhepr.2020.100134
[10]   Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma [J].
Alsina, Angel ;
Kudo, Masatoshi ;
Vogel, Arndt ;
Cheng, Ann-Lii ;
Tak, Won Young ;
Ryoo, Baek-Yeol ;
Evans, Thomas R. Jeffry ;
Lopez Lopez, Carlos ;
Daniele, Bruno ;
Misir, Soamnauth ;
Ren, Min ;
Izumi, Namiki ;
Qin, Shukui ;
Finn, Richard S. .
LIVER CANCER, 2020, 9 (01) :93-104